Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prucalopride in Constipation Predominant IBS
NCT04757493Phase 3Unknown
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Prucalopride Group with Placebo Group (2 arms). Primary endpoints: IBS-Symptom Severity Score at 6 weeks and IBS-Quality of Life at 6 weeks. Status: unknown.
02
Drugs
prucalopride
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT04757493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04757493.